Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTAWHL)

• Drug Name: AM251 Drug Info
• Synonyms: AM251; 183232-66-8; AM-251; AM 251; UNII-3I4FA44MAI; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 3I4FA44MAI; CHEMBL285932; CHEBI:90724; MFCD01861181; CPD000466284; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2125
  ChEBI ID: CHEMBL285932
  CAS Number: CAS 183232-66-8
  TTD Drug ID: DMTAWHL

Molecule-Related Drug Atlas

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[6]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[7]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[8]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[9]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[10]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[11]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[12]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[13]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[14]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[15]

Drug(s) Affected By Ribonuclease H1 (RNASEH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[19]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[20]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[21]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[22]
Testosterone undecanoate	DMZO10Y	Hypogonadism	5A61.0	Approved	[23]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[22]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[16]

Drug(s) Affected By SUN domain-containing protein 1 (SUN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[24]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[19]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[31]

Drug(s) Affected By Mitofusin-2 (MFN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[32]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[33]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[35]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[36]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[37]

Drug(s) Affected By Caveolae-associated protein 2 (CAVIN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[38]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[41]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[19]

Drug(s) Affected By Argininosuccinate synthase (ASS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[46]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[47]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[48]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[49]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[46]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[50]

Drug(s) Affected By Heat shock cognate 71 kDa protein (HSPA8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[52]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[53]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[55]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[58]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[59]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[60]

Drug(s) Affected By Regulator of chromosome condensation (RCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[62]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[65]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[66]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[61]

Drug(s) Affected By DNA replication licensing factor MCM3 (MCM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[69]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[70]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[71]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[72]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]

Drug(s) Affected By Replication protein A 70 kDa DNA-binding subunit (RPA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[74]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[75]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[76]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[78]

Drug(s) Affected By Protein S100-A2 (S100A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[79]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[81]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[82]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]

Drug(s) Affected By Peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[83]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[85]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[83]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[86]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[87]

Drug(s) Affected By DNA replication licensing factor MCM5 (MCM5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[88]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]

Drug(s) Affected By DNA damage-inducible transcript 3 protein (DDIT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[89]
Triacetin	DM0AEPG	Onychomycosis	EE12.1	Approved	[90]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[52]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[91]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[92]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[93]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[94]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[95]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]

Drug(s) Affected By Flap endonuclease 1 (FEN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[97]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[93]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[70]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[99]

Drug(s) Affected By Adenylyl cyclase-associated protein 2 (CAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[20]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[102]

Drug(s) Affected By Replication factor C subunit 5 (RFC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[103]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[99]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[78]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[104]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[105]

Drug(s) Affected By Condensin-2 complex subunit D3 (NCAPD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[106]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[104]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[19]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[21]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[107]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]

Drug(s) Affected By Neutral amino acid transporter A (SLC1A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[108]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[109]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[110]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[110]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[109]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[104]

Drug(s) Affected By Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[111]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[112]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[113]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[114]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]

Drug(s) Affected By Cysteine--tRNA ligase, cytoplasmic (CARS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[111]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[115]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[116]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[110]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[115]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[117]

Drug(s) Affected By Serine--tRNA ligase, cytoplasmic (SARS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Haloperidol	DM96SE0	Delirium		Approved	[78]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[110]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[78]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[78]

Drug(s) Affected By Poly(A) polymerase alpha (PAPOLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Bortezomib	DMNO38U	Leukemia		Approved	[118]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[119]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[120]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[121]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[61]

Drug(s) Affected By CCAAT/enhancer-binding protein gamma (CEBPG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[122]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[124]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[125]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[21]

Drug(s) Affected By Sestrin-2 (SESN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[89]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[126]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[115]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[109]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[115]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[127]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[89]

Drug(s) Affected By Actin-related protein 2/3 complex subunit 4 (ARPC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[128]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[129]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[130]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[16]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[131]

Drug(s) Affected By Spectrin beta chain, non-erythrocytic 1 (SPTBN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[79]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[132]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[133]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[128]

Drug(s) Affected By Large neutral amino acids transporter small subunit 1 (SLC7A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[134]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[75]
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[70]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[108]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[85]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[47]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[135]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[134]

Drug(s) Affected By Lamin-B2 (LMNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[136]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[137]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[138]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[139]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[141]

Drug(s) Affected By Neuronal acetylcholine receptor subunit beta-3 (CHRNB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[142]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[128]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[143]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[144]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[31]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[106]

Drug(s) Affected By Serine/arginine-rich splicing factor 1 (SRSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[53]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[142]
Bortezomib	DMNO38U	Leukemia		Approved	[118]

Drug(s) Affected By ATP-dependent RNA helicase A (DHX9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[53]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[145]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[20]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[146]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[100]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[147]

Drug(s) Affected By 116 kDa U5 small nuclear ribonucleoprotein component (EFTUD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[148]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[130]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[149]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[150]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[151]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[25]
PP-242	DM2348V	Discovery agent	N.A.	Investigative	[152]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[131]

Drug(s) Affected By Astrocytic phosphoprotein PEA-15 (PEA15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[125]

Drug(s) Affected By MFS-type transporter SLC18B1 (SLC18B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]

Drug(s) Affected By Protein FRA10AC1 (FRA10AC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[111]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[31]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[25]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[25]
methyl p-hydroxybenzoate	DMO58UW	Discovery agent	N.A.	Investigative	[154]

Drug(s) Affected By SURP and G-patch domain-containing protein 2 (SUGP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[24]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[50]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[19]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[155]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[155]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]

Drug(s) Affected By Nuclear receptor coactivator 7 (NCOA7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[115]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[47]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[156]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[32]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[115]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[81]

Drug(s) Affected By DNA repair and recombination protein RAD54-like (RAD54L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[157]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[158]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[119]

Drug(s) Affected By Signal transducing adapter molecule 1 (STAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[19]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[159]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[160]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[161]

Drug(s) Affected By Histone H2A type 1-C (H2AC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[162]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[72]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[81]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[163]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[164]

Drug(s) Affected By RCC1-like G exchanging factor-like protein (RCC1L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[81]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[128]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[165]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[166]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[167]
Hexadecanoic acid	DMWUXDZ	Discovery agent	N.A.	Investigative	[168]

Drug(s) Affected By Tribbles homolog 3 (TRIB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[89]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[169]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[170]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[115]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[109]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[135]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[115]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[41]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[171]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[122]

Drug(s) Affected By Mitochondrial inner membrane protease subunit 2 (IMMP2L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[172]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[173]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[123]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[174]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[31]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[106]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[81]

Drug(s) Affected By Transmembrane protein 126A (TMEM126A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[123]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[174]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[175]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[31]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[166]
Deguelin	DMXT7WG	Esophageal squamous cell carcinoma	2E60.1	Investigative	[176]

Drug(s) Affected By Rac GTPase-activating protein 1 (RACGAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[53]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[177]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[99]

Drug(s) Affected By Probable E3 ubiquitin-protein ligase IRF2BPL (IRF2BPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[178]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[125]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]

Drug(s) Affected By Tetraspanin-10 (TSPAN10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[179]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[180]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[31]

Drug(s) Affected By RWD domain-containing protein 1 (RWDD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[119]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[181]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[182]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[81]

Drug(s) Affected By Coiled-coil domain-containing protein 86 (CCDC86)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[85]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[183]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[184]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[125]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[185]

Drug(s) Affected By DNA damage-inducible transcript 4 protein (DDIT4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[89]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[186]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[187]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[188]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[109]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[156]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[127]

Drug(s) Affected By cAMP-regulated phosphoprotein 21 (ARPP21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[49]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[31]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[106]

Drug(s) Affected By Chemokine-like factor (CKLF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[142]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[185]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[121]

Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-5 (ATF5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[190]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[62]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[191]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[192]

Drug(s) Affected By General transcription factor 3C polypeptide 5 (GTF3C5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[125]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[107]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[31]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[25]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[193]

Drug(s) Affected By Transforming acidic coiled-coil-containing protein 3 (TACC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[194]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[195]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[195]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[28]

Drug(s) Affected By Proton-coupled zinc antiporter SLC30A1 (SLC30A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[97]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[196]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[197]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[108]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[85]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[109]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[122]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[198]

Drug(s) Affected By Zinc finger protein SNAI1 (SNAI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[199]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[200]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[201]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[202]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[170]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[203]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[204]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[42]
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[205]
Sanguinarine	DMDINFS	Dental plaque	DA08.4	Approved	[206]

Drug(s) Affected By Cadherin-1 (CDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[207]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[200]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[208]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[209]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[210]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[39]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[211]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[212]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[47]

Drug(s) Affected By Protein FosB (FOSB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[89]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[85]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[194]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[171]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[122]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[213]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[214]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[157]

Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[215]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[215]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[216]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[217]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[218]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[201]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[219]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[220]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[108]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[221]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Antagonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
116 kDa U5 small nuclear ribonucleoprotein component (EFTUD2)	OT3X7QG2	U5S1_HUMAN	Gene/Protein Processing	[3]
Actin-related protein 2/3 complex subunit 4 (ARPC4)	OT0ZE01B	ARPC4_HUMAN	Gene/Protein Processing	[3]
Adenylyl cyclase-associated protein 2 (CAP2)	OTC1WFNO	CAP2_HUMAN	Gene/Protein Processing	[3]
Argininosuccinate synthase (ASS1)	OT4ZMG0Q	ASSY_HUMAN	Gene/Protein Processing	[3]
Astrocytic phosphoprotein PEA-15 (PEA15)	OTKCKTSX	PEA15_HUMAN	Gene/Protein Processing	[3]
ATP-dependent RNA helicase A (DHX9)	OT5AAOQI	DHX9_HUMAN	Gene/Protein Processing	[3]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[4]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Gene/Protein Processing	[5]
cAMP-regulated phosphoprotein 21 (ARPP21)	OTWXZN5I	ARP21_HUMAN	Gene/Protein Processing	[3]
Caveolae-associated protein 2 (CAVIN2)	OTFHHDRU	CAVN2_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3317).
• [2] Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004 Apr;309(1):56-63.
• [3] Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett. 2006 Mar 20;580(7):1733-9.
• [4] Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacol Res. 2016 Sep;111:757-766. doi: 10.1016/j.phrs.2016.07.013. Epub 2016 Jul 14.
• [5] AM251 Suppresses Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells. PLoS One. 2016 Dec 9;11(12):e0167848. doi: 10.1371/journal.pone.0167848. eCollection 2016.
• [6] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [7] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [8] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [9] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [10] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [11] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [12] Company report (Gwpharm)
• [13] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [14] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [15] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [16] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [17] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [18] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [19] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [20] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [21] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [22] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [23] Levonorgestrel enhances spermatogenesis suppression by testosterone with greater alteration in testicular gene expression in men. Biol Reprod. 2009 Mar;80(3):484-92.
• [24] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [25] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [26] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [27] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [28] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [29] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [30] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [31] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [32] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [33] Lon protease: a novel mitochondrial matrix protein in the interconnection between drug-induced mitochondrial dysfunction and endoplasmic reticulum stress. Br J Pharmacol. 2017 Dec;174(23):4409-4429. doi: 10.1111/bph.14045. Epub 2017 Nov 7.
• [34] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [35] Melatonin prevents blood-retinal barrier breakdown and mitochondrial dysfunction in high glucose and hypoxia-induced in vitro diabetic macular edema model. Toxicol In Vitro. 2021 Sep;75:105191. doi: 10.1016/j.tiv.2021.105191. Epub 2021 May 5.
• [36] 5-Fluorouracil inhibits neural differentiation via Mfn1/2 reduction in human induced pluripotent stem cells. J Toxicol Sci. 2018;43(12):727-734. doi: 10.2131/jts.43.727.
• [37] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [38] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [39] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [40] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [41] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [42] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [43] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [44] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [45] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [46] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [47] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [48] Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83.
• [49] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [50] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [51] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [52] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [53] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [54] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [55] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [56] Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004 Mar 20;109(2):220-9. doi: 10.1002/ijc.11692.
• [57] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [58] Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009 Jun;8(6):3006-19.
• [59] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [60] Indomethacin and ibuprofen induce Hsc70 nuclear localization and activation of the heat shock response in HeLa cells. Biochem Biophys Res Commun. 2004 Jan 23;313(4):863-70. doi: 10.1016/j.bbrc.2003.12.018.
• [61] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [62] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [63] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [64] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [65] Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006 May 18;5:20. doi: 10.1186/1476-4598-5-20.
• [66] Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
• [67] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [68] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [69] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [70] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [71] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [72] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [73] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [74] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [75] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [76] XPC is essential for nucleotide excision repair of zidovudine-induced DNA damage in human hepatoma cells. Toxicol Appl Pharmacol. 2011 Mar 1;251(2):155-62. doi: 10.1016/j.taap.2010.12.009. Epub 2010 Dec 28.
• [77] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [78] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [79] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [80] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [81] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [82] Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin Cancer Res. 2007 Sep 1;13(17):5219-25. doi: 10.1158/1078-0432.CCR-07-0816.
• [83] Mitochondrial Thioredoxin System as a Modulator of Cyclophilin D Redox State. Sci Rep. 2016 Mar 15;6:23071. doi: 10.1038/srep23071.
• [84] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [85] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [86] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [87] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [88] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [89] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [90] Induction of CCAAT/enhancer-binding protein-homologous protein by cigarette smoke through the superoxide anion-triggered PERK-eIF2 pathway. Toxicology. 2011 Sep 5;287(1-3):105-12. doi: 10.1016/j.tox.2011.06.005. Epub 2011 Jun 15.
• [91] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [92] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [93] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [94] High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
• [95] Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.
• [96] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [97] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [98] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [99] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [100] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [101] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [102] High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2058-63.
• [103] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [104] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [105] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [106] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [107] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [108] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [109] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [110] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [111] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [112] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [113] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [114] Sevoflurane-mediated activation of p38-mitogen-activated stresskinase is independent of apoptosis in Jurkat T-cells. Anesth Analg. 2008 Apr;106(4):1150-60, table of contents. doi: 10.1213/ane.0b013e3181683d37.
• [115] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [116] Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin. 2003 Jul;24(7):646-50.
• [117] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [118] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [119] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [120] Identification of estrogen-induced genes downregulated by AhR agonists in MCF-7 breast cancer cells using suppression subtractive hybridization. Gene. 2001 Jan 10;262(1-2):207-14. doi: 10.1016/s0378-1119(00)00530-8.
• [121] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [122] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [123] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [124] Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15;66(24):12009-18.
• [125] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [126] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [127] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [128] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [129] Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.
• [130] Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes. Arch Toxicol. 2016 May;90(5):1103-15. doi: 10.1007/s00204-015-1545-2. Epub 2015 Jun 24.
• [131] Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.
• [132] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [133] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [134] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [135] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [136] New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids. Arch Toxicol. 2021 Aug;95(8):2691-2718. doi: 10.1007/s00204-021-03092-2. Epub 2021 Jun 20.
• [137] Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
• [138] Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics. 2011 Jan;10(1):M110.002170.
• [139] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [140] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [141] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [142] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [143] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [144] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [145] Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Liver Int. 2008 Aug;28(7):997-1010. doi: 10.1111/j.1478-3231.2008.01744.x. Epub 2008 Apr 15.
• [146] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [147] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [148] Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics. 2004 Jan 15;16(2):204-11.
• [149] Phosphoproteomics reveals resveratrol-dependent inhibition of Akt/mTORC1/S6K1 signaling. J Proteome Res. 2014 Dec 5;13(12):5734-42. doi: 10.1021/pr500714a. Epub 2014 Oct 29.
• [150] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [151] Gene expression changes associated with altered growth and differentiation in benzo[a]pyrene or arsenic exposed normal human epidermal keratinocytes. J Appl Toxicol. 2008 May;28(4):491-508.
• [152] Marine biogenics in sea spray aerosols interact with the mTOR signaling pathway. Sci Rep. 2019 Jan 24;9(1):675.
• [153] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [154] Transcriptome dynamics of alternative splicing events revealed early phase of apoptosis induced by methylparaben in H1299 human lung carcinoma cells. Arch Toxicol. 2020 Jan;94(1):127-140. doi: 10.1007/s00204-019-02629-w. Epub 2019 Nov 20.
• [155] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [156] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [157] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [158] New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines. Breast Cancer Res. 2006;8(1):R1. doi: 10.1186/bcr1362. Epub 2005 Dec 9.
• [159] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [160] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
• [161] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [162] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [163] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [164] Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
• [165] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [166] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [167] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [168] Exposure to dietary fatty acids oleic and palmitic acid alters structure and mechanotransduction of intestinal cells in vitro. Arch Toxicol. 2023 Jun;97(6):1659-1675. doi: 10.1007/s00204-023-03495-3. Epub 2023 Apr 29.
• [169] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [170] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [171] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [172] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [173] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [174] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [175] BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014 Feb 15;20(4):912-25.
• [176] Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.
• [177] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [178] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [179] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [180] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [181] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [182] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [183] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [184] Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
• [185] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [186] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [187] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [188] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [189] Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells. BMB Rep. 2010 Sep;43(9):599-603. doi: 10.5483/BMBRep.2010.43.9.599.
• [190] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [191] Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia. EBioMedicine. 2017 Oct;24:147-158. doi: 10.1016/j.ebiom.2017.09.022. Epub 2017 Sep 19.
• [192] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
• [193] Persistence of epigenomic effects after recovery from repeated treatment with two nephrocarcinogens. Front Genet. 2018 Dec 3;9:558.
• [194] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [195] Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
• [196] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [197] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [198] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [199] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [200] Manganese superoxide dismutase induces migration and invasion of tongue squamous cell carcinoma via H2O2-dependent Snail signaling. Free Radic Biol Med. 2012 Jul 1;53(1):44-50. doi: 10.1016/j.freeradbiomed.2012.04.031. Epub 2012 May 9.
• [201] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [202] Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-/Smad signaling pathways. Cell Biol Toxicol. 2021 Jun;37(3):479-496. doi: 10.1007/s10565-020-09562-0. Epub 2020 Oct 17.
• [203] Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Toxicol Sci. 2015 Jan;143(1):156-64. doi: 10.1093/toxsci/kfu218. Epub 2014 Oct 10.
• [204] In vitro antitumoral effects of the steroid ouabain on human thyroid papillary carcinoma cell lines. Environ Toxicol. 2021 Jul;36(7):1338-1348. doi: 10.1002/tox.23130. Epub 2021 Mar 24.
• [205] Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol. 2007 Sep;293(3):F723-31. doi: 10.1152/ajprenal.00480.2006. Epub 2007 Jun 27.
• [206] Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells. Chem Biol Interact. 2009 May 15;179(2-3):185-91. doi: 10.1016/j.cbi.2008.11.009. Epub 2008 Nov 21.
• [207] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [208] Nitric oxide causes anoikis through attenuation of E-cadherin and activation of caspase-3 in human gastric carcinoma AZ-521 cells infected with Mycoplasma hyorhinis. J Vet Med Sci. 2010 Jul;72(7):869-74.
• [209] Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci. 1999 Aug;112 ( Pt 16):2657-66. doi: 10.1242/jcs.112.16.2657.
• [210] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [211] Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochem Biophys Res Commun. 2009 Mar 13;380(3):614-9. doi: 10.1016/j.bbrc.2009.01.134. Epub 2009 Jan 27.
• [212] Regulation of epithelial cell morphology and functions approaching to more in vivo-like by modifying polyethylene glycol on polysulfone membranes. PLoS One. 2012;7(4):e36110.
• [213] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [214] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [215] Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
• [216] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [217] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [218] ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
• [219] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [220] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [221] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.